Competitive Landscape, Trends, Structure, Recent Mergers and Acquisitions, Brand Name Company Involvement

Dublin, May 31, 2021 (GLOBE NEWSWIRE) – The Global Generic Drugs Market 2020-2025 report has been added Offer.

The global generic market is expected to grow from USD 411.6 billion in 2020 to USD 650.3 billion in 2025, with an average annual growth rate (CAGR) of 9.6% for the period 2020-2025.

The type and structure of the generics industry will be discussed with profiles of over 20 leading generics manufacturers and an update on M&A activities. Five-year sales forecasts are made for the national markets and the most important therapeutic categories of the products concerned.

This report is published at a time when the pharmaceutical industry is facing more radical challenges and changes than it has been in the last half century. The global economic recession of 2008 had a profound impact on an industry that typically can withstand the usual ups and downs of business. Aside from the sometimes painful process of cutting costs and restructuring, the industry has had to face the fact that its trading environment has changed radically as all customers are now aware of prices.

During this critical time, the pharmaceutical world went through a phase for which the “Patent Cliff” label was coined. A stream of blockbuster drugs has begun to lose patent protection and R&D pipelines have been unable to produce satisfactory supplies of substitute products. Doors have been opened for generic drug companies to do what they do best: offer low-cost alternatives.

And there is an added complexity. Over the past two decades, advances in biotechnology have led to the advent of a generation of biotherapeutics that are often more effective than traditional small molecule drugs in treating their target diseases. The earliest of these biotherapeutics are now losing their patent protection, and this offers another option for generic copies – although, as will be seen, this is a technically demanding area. Indeed, the challenges faced by “originator” companies – the major suppliers of private label pharmaceuticals – are being met by those faced by generic suppliers.

The story goes on

Generic suppliers initially relied on low cost as their main market advantage. This became a powerful argument as public health departments in most European countries that operate national health systems introduced measures to curb drug spending. In the USA, developments in managed care had a similar effect. Everywhere these cost-cutting exercises preferred generic drugs.

However, the low price argument that had been the main rationale behind generic drugs countered the commercial promise of this industrial sector. This happened in part because the appeal (and thus the high sales potential) of blockbuster drugs persisted after those drugs lost their patent coverage. Generic companies vied with each other to introduce low-cost copies, and they sought to undercut each other until a year after the original brand’s patent expired, the average price for copy products was only 20% or less of the original.

In some cases, the price competition for generics was fueled by government reimbursement measures, which favored inexpensive drugs and thus tended to trigger further price reductions among generic competitors.

This development had two far-reaching effects. First, the weaker generic drug companies were weeded out in favor of companies that had the resources and the determination to exist in an environment where profit margins were slashed, sometimes to less than 10%. One of the survival strategies of these manufacturers was to expand their attractiveness beyond pure cost reduction and to include, for example, “super-generic” products with added value, often in the form of special delivery formulations.

Company profiles of the leading companies in the global generics market, including Aspen, Cipla, Lupine, Pfizer, Sanofi, Sun Pharmaceuticals and Teva Pharmaceuticals

Main topics covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Effects of COVID-19

  • Short term effects on the pharmaceutical industry

  • Long-term effects on the pharmaceutical industry

  • Impact of COVID-19 on the Generic Drugs Market

  • Impact on the supply chain

Chapter 5 The Era of New Generics

Chapter 6 Major Problems in Generic Drugs Market

  • Regulatory environment

  • US

  • European Union

  • Japan

  • Regulation of biosimilars

  • EU regulations

  • Developing situation in the US

  • Usage fees

  • Big Pharma Defense Strategies

  • Approved generics

  • Usage fees

  • Changing the climate for generics

  • Situation in Europe

  • Patents and IP

  • Supplementary protection certificates

Chapter 7 Global Generic Drugs Market

  • Global pharmaceutical market: brand name and generics

  • Global generic market

  • Market opportunities by product class

  • Market shares of drugs by therapeutic area

Chapter 8 Market Breakdown by Region

Chapter 9 Industry Trends

  • Competitive landscape

  • Market trends

  • Structure of the generic industry

  • Recent mergers and acquisitions

  • Brand name corporate participation

Chapter 10 Company Profiles

  • Aspen Holdings

  • Cipla Inc.

  • Fresenius Kabi

  • Lupine Ltd.

  • Mylan Inc.

  • Pfizer Inc.

  • Sandoz International GmbH

  • Sanofi

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

Chapter 11 Other International Companies

Please visit for more information on this report

CONTACT: CONTACT: Laura Wood, Senior Press Manager For EST office hours, call 1-917-300-0470 at 353-1-416-8900

Comments are closed.